NEW HETEROARYL AMIDE DERIVATIVES AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASES 1 AND/OR 2 (HDAC1-2)
申请人:Medibiofarma, S.L.
公开号:US20200138808A1
公开(公告)日:2020-05-07
The present invention relates to novel heteroaryl amide derivatives of formula (1)
as selective inhibitors of histone deacetylase 1 and 2 (hdac1-2) to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said compounds for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by inhibition the activity of histone deacetylase class I, particularly HDAC1 and HDAC2, such as cancer, neurodegenerative diseases, Infectious diseases, inflammatory diseases, heart failure and cardiac hypertrophy, diabetes, polycystic kidney disease, sickle cell disease and β-thalassemia disease and to methods for the treatment of the disesases mentioned above.
该发明涉及一种新型杂环酰胺衍生物,其化学式为(1),作为组织脱乙酰酶1和2(HDAC1-2)的选择性抑制剂,涉及其制备方法,包括所述化合物的药物组合物,以及利用所述化合物制造用于治疗可以通过抑制组织脱乙酰酶I类活性而改善的病理状况或疾病的药物,特别是HDAC1和HDAC2,如癌症、神经退行性疾病、传染病、炎症性疾病、心力衰竭和心肌肥大、糖尿病、多囊肾病、镰状细胞病和β-地中海贫血病,以及治疗上述疾病的方法。